Wojciech Jerzy Piotrowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9339097/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Longitudinal and Comparative Measures of Serum Chitotriosidase and YKL-40 in Patients With Idiopathic Pulmonary Fibrosis. Frontiers in Immunology, 2022, 13, 760776.	4.8	11
2	Clinical significance of CD34, podoplanin and Ki-67 expression in patients with locally advanced squamous cell cervical carcinoma. Journal of Obstetrics and Gynaecology, 2022, , 1-7.	0.9	0
3	Review: Serum Biomarkers of Lung Fibrosis in Interstitial Pneumonia with Autoimmune Features—What Do We Already Know?. Journal of Clinical Medicine, 2022, 11, 79.	2.4	12
4	The prognostic value of fixed time and self-paced walking tests in patients diagnosed with idiopathic pulmonary fibrosis. Advances in Respiratory Medicine, 2021, 89, 49-54.	1.0	3
5	Eosinopenia and neutrophil-to-lymphocyte count ratio as prognostic factors in exacerbation of COPD. Scientific Reports, 2021, 11, 4804.	3.3	12
6	Gender differences in health-related quality of life measured by the Sarcoidosis Health Questionnaire. Scientific Reports, 2021, 11, 10242.	3.3	5
7	Serial Measurements of Circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and Periostin in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: An Exploratory Study. Journal of Clinical Medicine, 2021, 10, 3864.	2.4	14
8	Assessment of cervical vascularization density in patients with locally advanced squamous cell cervical carcinoma evaluated in colour Doppler and power Doppler functions. Archives of Gynecology and Obstetrics, 2021, , 1.	1.7	1
9	Proteomic profiling of peripheral blood and bronchoalveolar lavage fluid in interstitial lung diseases: an explorative study. ERJ Open Research, 2021, 7, 00489-2020.	2.6	4
10	Air Pollution—An Overlooked Risk Factor for Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2021, 10, 77.	2.4	23
11	The Role of Interaction between Mitochondria and the Extracellular Matrix in the Development of Idiopathic Pulmonary Fibrosis. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-12.	4.0	11
12	Progressive fibrosis in interstitial lung diseases — proposed definition and management. Advances in Respiratory Medicine, 2021, 89, 505-510.	1.0	0
13	E-cigarette use among young adults in Poland: Prevalence and characteristics of e-cigarette users. Advances in Medical Sciences, 2020, 65, 437-441.	2.1	6
14	A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study. BMC Pulmonary Medicine, 2020, 20, 122.	2.0	9
15	Diagnostic and treatment standards in idiopathic pulmonary fibrosis in the era of antifibrotic drugs in Poland: A real-world practice survey. Advances in Respiratory Medicine, 2020, 87, 221-230.	1.0	2
16	Guidelines of the Polish Respiratory Society for Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Advances in Respiratory Medicine, 2020, 88, 42-94.	1.0	19
17	The role of bronchoscopy in diagnosis of chronic cough in adults: a retrospective single-center study. Advances in Respiratory Medicine, 2020, 88, 406-411.	1.0	3
18	Unusually high plasma values of many tumour markers in a patient with idiopathic pulmonary fibrosis. Ginekologia Polska, 2020, 91, 101-101.	0.7	0

Wojciech Jerzy Piotrowski

#	Article	IF	CITATIONS
19	Diagnosis of Sarcoidosis—The Updated ATS 2020 Recommendations through the Prism of Everyday Clinical Practice. Advances in Respiratory Medicine, 2020, 88, 293-296.	1.0	3
20	Epithelial alarmin levels in exhaled breath condensate in patients with idiopathic pulmonary fibrosis: A pilot study. Clinical Respiratory Journal, 2019, 13, 652-656.	1.6	6
21	Telomere Abnormalities in the Pathobiology of Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2019, 8, 1232.	2.4	24
22	Untypical Manifestations of Granulomatosis with Polyangiitis—A Review of the Literature. SN Comprehensive Clinical Medicine, 2019, 1, 616-626.	0.6	6
23	<p>Overexpression of chitotriosidase and YKL-40 in peripheral blood and sputum of healthy smokers and patients with chronic obstructive pulmonary disease</p> . International Journal of COPD, 2019, Volume 14, 1611-1631.	2.3	12
24	Epithelial Alarmins in Serum and Exhaled Breath in Patients with Idiopathic Pulmonary Fibrosis: A Prospective One-Year Follow-Up Cohort Study. Journal of Clinical Medicine, 2019, 8, 1590.	2.4	10
25	Sarcoidosis and calcium homeostasis disturbances—Do we know where we stand?. Chronic Respiratory Disease, 2019, 16, 147997311987871.	2.4	17
26	The assessment of spectral Doppler parameters in uterine arteries of patients with locally advanced squamous cell cervical cancer. Ginekologia Polska, 2019, 90, 622-627.	0.7	1
27	Mitochondrial functioning abnormalities observed in blood platelets of chronic smoke-exposed guinea pigs – a pilot study. International Journal of COPD, 2018, Volume 13, 3707-3717.	2.3	3
28	Innate Immune Response to Viral Infections in Primary Bronchial Epithelial Cells is Modified by the Atopic Status of Asthmatic Patients. Allergy, Asthma and Immunology Research, 2018, 10, 144.	2.9	23
29	A pilot study of daily telemonitoring to predict acute exacerbation in chronic obstructive pulmonary disease. International Journal of Medical Informatics, 2018, 116, 46-51.	3.3	19
30	Is bronchoscopy always justified in diagnosis of haemoptysis?. Advances in Respiratory Medicine, 2018, 86, 13-16.	1.0	3
31	Is bronchoscopy always justified in diagnosis of haemoptysis? Response to the letter of Tamura et al Advances in Respiratory Medicine, 2018, 86, 111-111.	1.0	1
32	Skin condition and its relationship to systemic inflammation in chronic obstructive pulmonary disease. International Journal of COPD, 2017, Volume 12, 2407-2415.	2.3	7
33	Thyroid Gland in Chronic Obstructive Pulmonary Disease. Advances in Respiratory Medicine, 2017, 85, 28-34.	1.0	5
34	Idiopathic pulmonary fibrosis (IPF) ― common practice in Poland before the "antifibrotic drugs era― Advances in Respiratory Medicine, 2017, 85, 136-142.	1.0	4
35	The Utility of Selected Questionnaires in the Assessment of Fatigue, Depression and Health Quality in Post-Sarcoidosis Fatigue Syndrome. Advances in Respiratory Medicine, 2017, 85, 313-321.	1.0	10
36	The Role of Mitochondria and Oxidative/Antioxidative Imbalance in Pathobiology of Chronic Obstructive Pulmonary Disease. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-15.	4.0	63

#	Article	IF	CITATIONS
37	Altered Cyclooxygenase-2 Expression in Pulmonary Sarcoidosis is not Related to Clinical Classifications. Inflammation, 2016, 39, 1302-1309.	3.8	1
38	Altered miRNA expression in pulmonary sarcoidosis. BMC Medical Genetics, 2016, 17, 2.	2.1	29
39	Fatigue Syndrome in Sarcoidosis. Pneumonologia I Alergologia Polska, 2016, 84, 244-250.	0.6	4
40	Immunoexpression of TGF-β/Smad and VEGF-A proteins in serum and BAL fluid of sarcoidosis patients. BMC Immunology, 2015, 16, 58.	2.2	15
41	Pulmonary manifestations of inflammatory bowel disease. Archives of Medical Science, 2015, 6, 1179-1188.	0.9	58
42	Telemedicine for the management of COPD — near future or a hazy idea?. Pneumonologia I Alergologia Polska, 2015, 83, 413-414.	0.6	0
43	Mycobacterium tuberculosis as a sarcoid factor? A case report of family sarcoidosis. American Journal of Case Reports, 2014, 15, 216-220.	0.8	12
44	Chemokine receptor CXCR3 ligands in bronchoalveolar lavage fluid: associations with radiological pattern, clinical course, and prognosis in sarcoidosis. Polish Archives of Internal Medicine, 2014, 124, 395-402.	0.4	5
45	Exhaled breath 8-isoprostane as a marker of asthma severity. Archives of Medical Science, 2012, 3, 515-520.	0.9	17
46	Somatostatin receptor scintigraphy in sarcoidosis: relation to selected clinical and laboratory markers. Polish Archives of Internal Medicine, 2012, 122, 98-106.	0.4	3
47	Correlation between Eicosanoids in Bronchoalveolar Lavage Fluid and in Exhaled Breath Condensate. Disease Markers, 2011, 30, 213-220.	1.3	28
48	The selected genetic polymorphisms of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis. Medical Science Monitor, 2011, 17, CR598-CR607.	1.1	30
49	Exhaled 8-isoprostane in sarcoidosis: relation to superoxide anion production by bronchoalveolar lavage cells. Inflammation Research, 2010, 59, 1027-1032.	4.0	10
50	Exhaled 8-isoprostane as a prognostic marker in sarcoidosis. A short term follow-up. BMC Pulmonary Medicine, 2010, 10, 23.	2.0	17
51	Hepatocyte growth factor in exhaled breath and BAL fluid in sarcoidosis. Pneumonologia I Alergologia Polska, 2010, 78, 187-91.	0.6	1
52	Metalloproteinases MMP-9, MMP-2 and their tissue inhibitors TIMP-1, TIMP-2 in peripheral transbronchial lung biopsies of patients with sarcoidosis. , 2009, 119, 628-35.		4
53	Superoxide anion production by bronchoalveolar lavage cells in relation to cellular composition and lung function in sarcoidosis and chronic bronchitis. , 2009, 119, 777-84.		3
54	Eicosanoids in Exhaled Breath Condensate and BAL Fluid of Patients With Sarcoidosis. Chest, 2007, 132, 589-596.	0.8	44

#	Article	IF	CITATIONS
55	Atypical Lung Changes in a 19-Year-Old Woman with Crohn's Disease. Lung, 2007, 185, 189-190.	3.3	7
56	Concentration of TBA-reactive substances in type II pneumocytes exposed to oxidative stress. Archivum Immunologiae Et Therapiae Experimentalis, 2004, 52, 435-40.	2.3	4
57	Effect of Paraquat Intoxication and Ambroxol Treatment on Hydrogen Peroxide Production and Lipid Peroxidation in Selected Organs of Rat. , 1996, 16, 501-507.		36